In Basic Science Commentary The nuclear factor erythroid 2-related factor 2 (Nrf2), a master transcriptional regulator of antioxidant and detoxification genes, has recently emerged as an important therapeutic target for various diseases, including neurologic disorders (1). Nrf2, a ubiquitous member of the cap'n'collar transcription factors, is activated by cellular stress and initiates transcription of a diverse set of genes, such as antioxidant defense, drug transporters, metabolic enzymes, and transcription factors, by binding to the antioxidant response elements (AREs) or electrophile response elements (2). Activation of the Nrf2 pathway has been shown to be neuroprotective in various animal models, which supports the concept of therapeutic targeting with Nrf2 activators as a viable pathway for neurologic disorders. This is exemplified by the recent introduction of dimethyl fumarate, a weak Nrf2 activator for the treatment of nonremitting multiple sclerosis (3). One reason for considering the Nrf2 pathway in epilepsy arises from the recognition that oxidative stress reflected by altered steady-state glutathione levels occurs with epileptogenesis (4). Moreover, the ketogenic